Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01406080
Other study ID # BR.10.002
Secondary ID
Status Completed
Phase Phase 3
First received July 28, 2011
Last updated April 5, 2017
Start date January 2013
Est. completion date November 2015

Study information

Verified date January 2016
Source Galderma Brasil Ltda.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to:

1. Evaluate the efficacy of Adapalene gel 0.3% compared to Tretinoin Emollient cream 0.05%, reducing signs of cutaneous photoageing, measured trough photonumeric scale evaluation, investigator evaluation of global response to treatment and subject's evaluation of improvement.

2. Evaluate the safety and tolerability of Adapalene Gel 0.3%, compared to Tretinoin Emollient cream 0.05% during 24 weeks of treatment.

The study has the clinical hypothesis that Adapalene Gel 0.3% is as effective as Tretinoin Emollient cream 0.05% in the treatment of cutaneous photoaging.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 35 Years to 55 Years
Eligibility Inclusion Criteria:

- Patients presenting at least some score on periorbital or frontal wrinkle or melanosis and at maximum a "Severe" score on any of the criteria considered in evaluating cutaneous photoaging extension, based on the table for assessing Cutaneous Photoaging Extent;

- Male and female patients aged at least 35 years and maximum of 55 years, with skin phototype of I to IV, according to the T.B. Fitzpatrick's scale;

- Individuals who have mild to moderate cutaneous photoaging, i.e., score 2-6 in the overall assessment of cutaneous photoaging, based on the Griffiths scale;

- If female, individuals who cannot get pregnant (defined as post-menopausal the lack of menstrual bleeding for one year - or have undergone bilateral tubal ligation, hysterectomy or bilateral oophorectomy) or, if in childbearing age, patients who underwent urine pregnancy test with negative results. Patients should be using an appropriate contraceptive method. In the case of oral contraceptives, the use must have been started at least one month before the study or 12 months in case of pills containing cyproterone. Patients should maintain the same contraceptive during the study and 1 additional month after completion;

- For subjects under treatment for a concomitant medical condition, type and dose must be stable for at least three months prior to study entry (at least one year, in the case of hormone replacement therapy) and should not change during the study. These drugs do not include the excluded drugs cited in exclusion criterion;

- Individuals able to avoid prolonged sun exposure, especially on the face during the study period and willing to use the proper techniques to avoid the sun, including the use of sunscreen provided during the study;

- Individuals able to follow the study instructions and who are willing to complete all required visits;

- Individuals who have signed the informed consent form before any study procedures;

Exclusion Criteria:

- Patients who have participated in another clinical trial for less than 30 days;

- Pregnant women, nursing mothers or women attempting to conceive;

- Female patients who started hormone replacement therapy for less than one year before entering the study;

- Individuals with a condition or who are in a situation that, in the opinion of the investigator, may put the objective of the study at risk, confound the results or even interfere with the individual participation. These include, but are not limited to:

1. Individuals with other facial skin disorders or dermatosis (scars, inflammatory acne, etc.) that can interfere with the clinical evaluation;

2. Patients with a history of treatment for photoaging using ablative laser technologies (such as carbon dioxide and Erbium: YAG) and / or non-ablative (Nd: YAG, Fractionated Erbium Glass, Diode, Infrared Light, Intense Pulsed Light, Radiofrequency, Pulsed Dye Laser), dermabrasion, medium or deep chemical peeling on face;

3. Individuals diagnosed with skin cancer (squamous cell carcinoma, melanoma) in the last 3 months prior to study entry;

4. Individuals not willing to refrain from any cosmetic procedure during the study period (e.g. other types of chemical peelings, microdermabrasion, etc.);

5. Individuals with significant medical history, concomitant disease or condition in which the investigator believes that participation in the study is not propitious;

- Patients with known sensitivity to retinoids or to any component of the study products;

- Patients with a diagnosis or history of keloids;

- Patients without the minimum wash-out period for the following treatments:

1. 2 weeks for topical alpha- hydroxy acid, glycolic acid, salicylic acid, lactic acid, betahydroxy acid on the face.

2. 2 weeks for topical products containing vitamin A, ascorbic acid, vitamin E on the face.

3. 2 weeks for topical corticosteroids.

4. 4 weeks for systemic corticosteroids.

5. 3 months for topical retinoids.

6. 1 year for oral retinoids.

- Patients who underwent superficial chemical peelings, microdermabrasion or exfoliation on the face in the last 3 months;

- Patients who applied botulinum toxin or soft tissue fillers for facial rejuvenation in the last 6 months and do not agree on not using these products during the study;

- Patients self-identified as "sensitive skin";

- Patients who are not willing or able to attend the study visits;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Adapalene
Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
Tretinoin
Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.

Locations

Country Name City State
Brazil Santa Casa de Belo Horizonte Belo Horizonte Minas Gerais
Brazil Hospital de Clínicas da Universidade Federal do Paraná Curitiba Paraná
Brazil Centro de Dermatologia Dona Libania Fortaleza Ceará
Brazil Universidade Federal de São Paulo - UNIFESP - UNICCO São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Galderma Brasil Ltda.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessing the extent of Cutaneous Photoaging at the end of treatment. Evaluation of Cutaneous Photoaging Extension at the end of treatment: the signs of cutaneous photoaging are evaluated by means of reduction of at least one point in any one of the following parameters: periorbital wrinkles, ephelides / melanosis, forehead wrinkles, tactile roughness (texture) and actinic keratosis. Baseline to week 24
Secondary Global Assessment of photoaging, based on the Griffiths photonumeric scale. The evaluator, blinded to the treatment, will assess the global degree of photoaging of the patient in all visits, based on photographic images of the Griffiths scale consisted of 5 categories (Periorbital Wrinkles, Ephelides / melanosis, Forehead Wrinkles, Tactile roughness (texture), Actinic Keratosis. These were evaluated on a scale from 0 - 4 (0 = Absent, 1 = Minimal, 2 = Mild, 3 = Moderate and 4 = Severe) with 0 being best and 4 being worst. week 24
Secondary Assessing the extent of Cutaneous Photoaging at each visit. The absolute values and changes of the Evaluation of Cutaneous Photoaging Extent in relation to baseline will be summarized by using frequency tables and at each visit and the groups will be compared. week 24
Secondary Evaluation of Improvement by the Investigator at Week 12 The evaluator, blinded to the treatment, will evaluate the improvement of the photoaging signs at week 12 using the scale 5 = important response, 4 = near complete response (˜ 90% improvement), 3 = marked response (˜ 75% improvement), 2 = moderate response (˜ 50% improvement), 1 = mild response (˜ 25% improvement), 0 = No answer, -1= Worsening. week 12
Secondary Evaluation of Improvement by the Investigator at Week 24 The evaluator, blinded to the treatment, will evaluate the improvement of the photoaging signs at week 12 using the scale 5 = important response, 4 = near complete response (˜ 90% improvement), 3 = marked response (˜ 75% improvement), 2 = moderate response (˜ 50% improvement), 1 = mild response (˜ 25% improvement), 0 = No answer, -1= Worsening. Week 24
Secondary Subject Assessment of improvement at week 24. Patients will evaluate the improvement perceived at week 24 using the following scale:0 = Improves hard to notice, 1 = A very small improvement, 2 = Small improvement, 3 = Moderate improvement, 4 = Major improvements. week 24
Secondary Anatomical-pathological assessment The difference between the treatment arms in epidermal thickness and 7.7 in the thickness of the granular layer will be detect at week 24. week 24
Secondary Digital morphometric assessment. The thickness of the stratum corneum, granular layer and the epithelium will be estimated week 24
See also
  Status Clinical Trial Phase
Completed NCT05271136 - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum N/A
Completed NCT05514782 - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum N/A
Completed NCT04911374 - An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream N/A
Completed NCT04586816 - Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging N/A
Completed NCT05039723 - Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational Phase 4
Not yet recruiting NCT05004909 - Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream N/A
Completed NCT06366503 - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation N/A
Completed NCT05027282 - Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment N/A
Not yet recruiting NCT06096649 - The Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged Skin N/A
Completed NCT03661697 - Combination Versus Laser Treatment Only N/A
Completed NCT03948945 - Efficacy and Safety of Profile HaloTM Mixed Fractional Laser on Treating of Facial and Neck Photoaging. N/A
Completed NCT06148558 - A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+ N/A
Enrolling by invitation NCT06188338 - A 56-day Clinical Study on Facial Skin Rejuvenation N/A
Recruiting NCT06195605 - Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin N/A
Not yet recruiting NCT04869852 - Effects of Mango Intake on Skin Health and Gut Microbiome Changes in Postmenopausal Women N/A
Not yet recruiting NCT02126644 - The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging Phase 2
Active, not recruiting NCT01372566 - Effect of Platelet Rich Plasma on Photoaged Skin Phase 1/Phase 2
Unknown status NCT00842907 - Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage Phase 2
Completed NCT03112863 - Comparison of the Cosmetic Effects of Bakuchiol and Retinol Early Phase 1
Recruiting NCT05386368 - RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients Phase 4